Microsoft's one-time retirement program will be open to U.S. workers at the senior director level and below whose years of employment and age add up to 70 or more. The company is also decoupling stock ...
Forbes contributors publish independent expert analyses and insights. Dr. Liz Doe Stone is the CEO of Top Tier Admissions. This voice experience is generated by AI. Learn more. This voice experience ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Replimune Group’s REPL share price is down 63% in the pre-market hours today after the company announced that the FDA has issued a second complete response letter (CRL) against its resubmitted ...
Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
Pittsburgh is locked into a pattern of cool weather that will continue for a couple of weeks. Paul Skenes threw eight brilliant innings in one of the best outings of the young star's career, Brandon ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
With elevated interest rates, limiting housing stock and existing owners staying put, buying a house has never been more challenging. First-time buyers need flexible down payment options, generous ...
Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions ...
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...
Hosted on MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results